製品番号: HY-14881

Bedaquiline

(別名: TMC207; R207910)

56 Cited Publications

カスタマーレビュー

Based on 56 publication(s) in Google Scholar

Bedaquiline (TMC207) is a diarylquinoline agent and inhibits Mycobacterium tuberculosis (Mtb) F1FO-ATP synthase through targeting of both the c- and the ε-subunit. Bedaquiline has uncoupler activity. Bedaquiline is used for the multi-agent resistant tuberculosis.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

純度: 99.98%
CAS 番号: 843663-66-1
分子式: C₃₂H₃₁BrN₂O₂
分子量:555.50

保管条件:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Bedaquiline 構造式

CAS 番号: 843663-66-1

容量

価格（税別）

在庫状況

数量

Amount: USD 0.00

* アイテムを追加する前、数量をご選択ください

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

生物活性
- 製品説明
- IC₅₀ & Target
- Cellular Effect
- 体外実験
- 臨床実験
化学情報
Publications (56)
溶剤 & 溶解度
- 体外
- 体内
純度とドキュメンテーション
参考文献
Help & FAQs
関連分類
Bioz

生物活性

製品説明

Bedaquiline (TMC207) is a diarylquinoline agent and inhibits Mycobacterium tuberculosis (Mtb) F1FO-ATP synthase through targeting of both the c- and the ε-subunit^[1]. Bedaquiline has uncoupler activity. Bedaquiline is used for the multi-agent resistant tuberculosis^[2].

IC₅₀ & Target

Mtb F1FO-ATP synthase^[1]

Antibiotic アイソフォーム固有の製品をすべて表示 :

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	CC₅₀	>64 μg/mL Compound: 1; TMC207,R207910	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 35636648]
Vero	CC₅₀	>50 μg/mL Compound: 1; TMC207,R207910	Cytotoxicity against African green monkey Vero cells Cytotoxicity against African green monkey Vero cells	[PMID: 35636648]
Vero	IC₅₀	>10 μg/mL Compound: 1	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay	[PMID: 29107541]
Vero	IC₅₀	>10 μg/mL Compound: 1; TMC207	Cytotoxicity against African green monkey Vero cells measured after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay Cytotoxicity against African green monkey Vero cells measured after 72 hrs by CellTiter 96 aqueous non-radioactive cell proliferation assay	[PMID: 30891129]
Vero	IC₅₀	>10 μg/mL Compound: 1; TMC207, Sirturo	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS-PMS assay	[PMID: 30792104]
Vero	IC₅₀	>10 μg/mL Compound: 1; TMC207, Sirturo	Cytotoxicity against African green monkey Vero cells measured after 72 hrs by MTT assay Cytotoxicity against African green monkey Vero cells measured after 72 hrs by MTT assay	[PMID: 30803745]
Vero	IC₅₀	>10 μM Compound: 2	Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS/PMS assay Cytotoxicity against African green monkey Vero cells after 72 hrs by MTS/PMS assay	[PMID: 29259747]
Vero	IC₅₀	4 μg/mL Compound: 1; BDQ	Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTS-PBS assay Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability incubated for 72 hrs by MTS-PBS assay	[PMID: 31810890]

体外実験

Bedaquiline inhibits the growth of TDR M. tuberculosis strains, with MIC values ranging from 0.125 to 0.5 mg/L^[2].
Among slowly growing mycobacteria (SGM), bedaquiline exhibits the highest activity against Mycobacterium avium with MIC₅₀ and MIC₉₀ values of 0.03 and 16 mg/L, respectively. Among rapidly growing mycobacteria (RGM), Mycobacterium abscessus subsp. abscessus (M. abscessus) and Mycobacterium abscessus subsp. massiliense (M. massiliense) seem more susceptible to bedaquiline than Mycobacterium fortuitum, with MIC₅₀ and MIC₉₀ values of 0.13 and >16 mg/L, respectively, for both species. Bedaquiline also shows moderate in vitro activity against NTM species^[3].
Bedaquiline has an excellent in vitro activity against Mycobacterium tuberculosis, including multidrug resistant M tuberculosis^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

臨床実験

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

化学情報

CAS 番号 843663-66-1
性状 Solid
分子量 555.50
分子式 C₃₂H₃₁BrN₂O₂
Color White to yellow
SMILES

BrC1=CC=C(N=C(OC)C([C@H]([C@@](C2=CC=CC3=C2C=CC=C3)(O)CCN(C)C)C4=CC=CC=C4)=C5)C5=C1
別名

TMC207; R207910
輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (56)

All Cell Imaging/StainingMicrobiological Assay

Sort by:

Journal Impact Factor

Cell

Clp-targeting BacPROTACs impair mycobacterial proteostasis and survival. [Abstract]

2023 May 11;186(10):2176-2192.e22. PMID: 37137307
Autophagy

Duloxetine ameliorates cerebral ischemic injury by inhibiting autophagy. [Abstract]

2026 Mar 5. PMID: 41787744
Nat Commun

Phenotypic drug susceptibility testing for Mycobacterium tuberculosis variant bovis BCG in 12 hours. [Abstract]

2025 May 10;16(1):4366. PMID: 40348759

Bedaquiline purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 May 10;16(1):4366. [Abstract]

Bedaquiline (BDQ) was effective on susceptible M. smegmatis already at 1× MIC (0.05 μg/mL).
Nat Commun

Intracellular localisation of Mycobacterium tuberculosis affects efficacy of the antibiotic pyrazinamide. [Abstract]

2021 Jun 21;12(1):3816. PMID: 34155215

Bedaquiline purchased from MedChemExpress. Usage Cited in: Nat Commun. 2021 Jun 21;12(1):3816. [Abstract]

Bedaquiline (BDQ) (2.5 μg/mL, 24 h) significantly enhanced Pyrazinamide (PZA)/Pyrazinoic acid (POA) accumulation in intracellular Mtb.
Adv Sci (Weinh)

Single-Mitochondrion ATP Profiling Directs Discovery of Targetable OXPHOS Dependency in Cancers. [Abstract]

2026 Apr;13(21):e13341. PMID: 41684301
mLife

Identification of a phenyl ester covalent inhibitor of caseinolytic protease and analysis of the ClpP1P2 inhibition in mycobacteria. [Abstract]

2025 Apr 15;4(2):155-168. PMID: 40313980
Eur J Med Chem

Design, synthesis and biological evaluation of (Quinazoline 4-yloxy)acetamide and (4-oxoquinazoline-3(4H)-yl)acetamide derivatives as inhibitors of Mycobacterium tuberculosis bd oxidase. [Abstract]

2022 Nov 15:242:114639. PMID: 35973312
Int J Pharm

A quality-by-design strategic approach for the development of bedaquiline-pretomanid nanoparticles as inhalable dry powders for TB treatment. [Abstract]

2024 Mar 25:653:123920. PMID: 38387819
J Clin Microbiol

Luciferase reporter mycobacteriophage (TM4:: GeNL) enables rapid assessment of drug susceptibilities and inducible macrolide resistance in Mycobacterium abscessus complex. [Abstract]

2025 Aug 20:e0084125. PMID: 40833127

Bedaquiline purchased from MedChemExpress. Usage Cited in: J Clin Microbiol. 2025 Aug 20:e0084125. [Abstract]

M. abscessus bedaquiline MIC90 values from TM4::GeNL DST, Sensititre RAPMYCO2 DST, MAB_2299c gene mutation-sMAB_4384 and MAB_2299c genotypes. Among the isolates tested, 35% (9/26) demonstrated Bedaquiline (BDQ) MICs greater than 0.5 µg/mL.
Commun Biol

The acetyltransferase CysE modulates virulence and drug resistance of Mycobacterium tuberculosis by interfering with oxidative stress responses. [Abstract]

2025 Oct 6;8(1):1425. PMID: 41053365

Bedaquiline purchased from MedChemExpress. Usage Cited in: Commun Biol. 2025 Oct 6;8(1):1425. [Abstract]

Minimum Inhibitory Concentration (MIC) determination of the ΔcysE in comparison to WT and Complement strains against anti-TB drugs: Bedaquilline (BDQ) (7 days).
Commun Biol

Development of tolerance to bedaquiline by overexpression of trypanosomal acetate: succinate CoA transferase in Mycobacterium smegmatis. [Abstract]

2025 Feb 6;8(1):187. PMID: 39915674
Front Microbiol

In vitro Antibacterial Activity of an FDA-Approved H+-ATPase Inhibitor, Bedaquiline, Against Streptococcus mutans in Acidic Milieus. [Abstract]

2021 Feb 25;12:647611. PMID: 33717046
Front Microbiol

Mycobacterial Cell Wall Synthesis Inhibitors Cause Lethal ATP Burst. [Abstract]

2018 Aug 15:9:1898. PMID: 30158918
Pharmaceuticals (Basel)

Bedaquiline-Loaded Solid Lipid Nanoparticles Drug Delivery in the Management of Non-Small-Cell Lung Cancer (NSCLC). [Abstract]

2023 Sep 15;16(9):1309. PMID: 37765117
Antibiotics (Basel)

Differential Regulation of Oxidative Burst by First Line Drugs Used Against Multi Drug-Resistant Tuberculosis in Naïve Human Innate Immune Cells. [Abstract]

2026 Jun 9;15(6):590. PMID: 42353714
Front Cell Infect Microbiol

Imaging the NADH:NAD+ Homeostasis for Understanding the Metabolic Response of Mycobacterium to Physiologically Relevant Stresses. [Abstract]

2016 Nov 8:6:145. PMID: 27878107
mBio

Bioenergetic Heterogeneity in Mycobacterium tuberculosis Residing in Different Subcellular Niches. [Abstract]

2021 Jun 29;12(3):e0108821. PMID: 34060333
ACS Infect Dis

Toward a Bactericidal Oral Drug Combination for the Treatment of Mycobacterium abscessus Lung Disease. [Abstract]

2025 Apr 1. PMID: 40168319
ACS Infect Dis

Intranasal Administration of Bedaquiline-Loaded Fucosylated Liposomes Provides Anti-Tubercular Activity while Reducing the Potential for Systemic Side Effects. [Abstract]

2024 Sep 13;10(9):3222-3232. PMID: 39136125
ACS Infect Dis

Identification of Chemical Scaffolds Targeting Drug-Resistant and Latent Mycobacterium tuberculosis through High-Throughput Whole-Cell Screening. [Abstract]

2024 Feb 9;10(2):513-526. PMID: 38238154
ACS Infect Dis

Two-Way Regulation of MmpL3 Expression Identifies and Validates Inhibitors of MmpL3 Function in Mycobacterium tuberculosis. [Abstract]

2021 Jan 8;7(1):141-152. PMID: 33319550
Nanomedicine

3D spheroid model reveals enhanced efficacy of mannose-decorated nanoparticles for TB treatment. [Abstract]

2025 Apr;20(8):777-789. PMID: 40099656
Antimicrob Agents Chemother

Incorporation of macrophage immune stresses into an intracellular assay of drug tolerance in Mycobacterium tuberculosis. [Abstract]

2025 Sep 11:e0079525. PMID: 40934365

Bedaquiline purchased from MedChemExpress. Usage Cited in: Antimicrob Agents Chemother. 2025 Sep 11:e0079525. [Abstract]

Bedaquiline (BDQ) showed efficacy against Mtb in activated BMDM^hs. Macrophages were infected with bacteria and treated with BDQ (0.63 and 2.5 μg/mL, 0-12 days).
Antimicrob Agents Chemother

Limited predictive power of known resistance genes for phenotypic drug resistance in clinical Mycobacterium abscessus complex from Beijing in China. [Abstract]

2025 May 27:e0184724. PMID: 40422286
Antimicrob Agents Chemother

An enoyl-ACP reductase inhibitor, NITD-916, expresses anti- Mycobacterium abscessus activity. [Abstract]

2025 May 23:e0024925. PMID: 40407337
Antimicrob Agents Chemother

Multidrug tolerance conferred by loss-of-function mutations in anti-sigma factor RshA of Mycobacterium abscessus. [Abstract]

2024 Oct 29:e0105124. PMID: 39470195
Antimicrob Agents Chemother

TBAJ-587, a novel diarylquinoline, is active against Mycobacterium abscessus. [Abstract]

2024 Oct 29:e0094524. PMID: 39470202
Antimicrob Agents Chemother

Activity of Oral Tebipenem-Avibactam in a Mouse Model of Mycobacterium abscessus Lung Infection. [Abstract]

2023 Feb 16;67(2):e0145922. PMID: 36688684
Antimicrob Agents Chemother

Nitric Oxide-Dependent Electron Transport Chain Inhibition by the Cytochrome bc1 Inhibitor and Pretomanid Combination Kills Mycobacterium tuberculosis. [Abstract]

2021 Aug 17;65(9):e0095621. PMID: 34152815
Antimicrob Agents Chemother

Heterologous Expression of ethA and katG in Mycobacterium marinum Enables the Rapid Identification of New Prodrugs Active against Mycobacterium tuberculosis. [Abstract]

2021 Mar 18;65(4):e01445-20. PMID: 33495223
Antimicrob Agents Chemother

TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus. [Abstract]

2020 Mar 24;64(4):e02404-19. PMID: 31964791
Antimicrob Agents Chemother

TBAJ-876 Displays Bedaquiline-Like Mycobactericidal Potency without Retaining the Parental Drug's Uncoupler Activity. [Abstract]

2020 Jan 27;64(2):e01540-19. PMID: 31712198
Antimicrob Agents Chemother

TBAJ-876 Retains Bedaquiline's Activity against Subunits c and ε of Mycobacterium tuberculosis F-ATP Synthase. [Abstract]

2019 Sep 23;63(10):e01191-19. PMID: 31358589
Microbiol Spectr

Evaluation of the post-antibiotic effect against Mycobacterium abscessus by a bioluminescence method. [Abstract]

2026 Apr 7;14(5):e0380525. PMID: 41944630
J Biol Chem

High efficacy of the F-ATP synthase inhibitor TBAJ-5307 against non-tuberculous mycobacteria in vitro and in vivo. [Abstract]

2024 Feb;300(2):105618. PMID: 38176652
Microbiol Spectr

GaMF1.39's antibiotic efficacy and its enhanced antitubercular activity in combination with clofazimine, Telacebec, ND-011992, or TBAJ-876. [Abstract]

2023 Dec 12;11(6):e0228223. PMID: 37982630
Microbiol Spectr

In Vitro Synergy Testing of Eravacycline in Combination with Clarithromycin and Rifabutin against Mycobacterium abscessus Complex. [Abstract]

2021 Sep 3;9(1):e0004521. PMID: 34132613
Vet Res

Mitochondrial dysfunction induced by bedaquiline as an anti-Toxoplasma alternative. [Abstract]

2023 Dec 19;54(1):123. PMID: 38115043
ACS Chem Biol

Investigate Natural Product Indolmycin and the Synthetically Improved Analogue Toward Antimycobacterial Agents. [Abstract]

2022 Jan 21;17(1):39-53. PMID: 34908399
Dis Model Mech

An anti-tuberculosis compound screen using a zebrafish infection model identifies an aspartyl-tRNA synthetase inhibitor. [Abstract]

2021 Dec 1;14(12):dmm049145. PMID: 34643222
Infect Immun

Mouse models of tuberculosis uniformly featuring hypoxic necrotic lesions and poor response to chemotherapy. [Abstract]

2026 Feb 9:e0057425. PMID: 41660838
J Pharm Biomed Anal

Characterization of stress degradation products of bedaquiline fumarate and bedaquiline by LC-PDA and LC-MS. [Abstract]

2023 Oct 25:235:115658. PMID: 37619292
SLAS Discov

A Novel Flow Cytometric Assay to Identify Inhibitors of RBPJ-DNA Interactions. [Abstract]

2020 Sep;25(8):895-905. PMID: 32567455
bioRxiv

Expanding the scope of Mycobacterium abscessus reference strains to improve pulmonary disease modeling. [Abstract]

2025 Nov 19:2025.11.19.689313. PMID: 41332525
bioRxiv

Mouse Models Uniformly Featuring Human-like Lesions Harboring Drug-tolerant Mycobacterium tuberculosis. [Abstract]

2025 Oct 17:2025.10.17.683099. PMID: 41279700
Authorea

2025 Sep 17.
bioRxiv

2025 July 04.
bioRxiv

2025 February 06.
bioRxiv

Netupitant Exhibits Potent Activity on Mycobacterium tuberculosis Persisters. [Abstract]

2024 Oct 30:2024.10.30.620736. PMID: 39554043
Research Square Preprint

2023 May 2.
Zoonoses

2023 Feb 2.
Università Vita-Salute San Raffaele

2022 Apr 08. 34.
Research Square Preprint

2022 Feb.
University of Manitoba

2022 Jan.
Research Square Preprint

2021 Nov.
University of Madras

2019, Jan.

溶剤 & 溶解度

体外:

DMSO : 12.5 mg/mL (22.50 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.8002 mL

9.0009 mL

18.0018 mL

5 mM

0.3600 mL

1.8002 mL

3.6004 mL

10 mM

0.1800 mL

0.9001 mL

1.8002 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

モル濃度計算機

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

濃度濃度

体積体積

分子量分子量

希釈計算機

濃度 _(開始) × 体積 _(開始) = 濃度 _(終了) × 体積 _(終了)

濃度 _(開始) 濃度 _(開始)

体積 _(開始) 体積 _(開始)

濃度 _(終了) 濃度 _(終了)

体積 _(終了) 体積 _(終了)

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.5 mg/mL (0.90 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 0.5 mg/mL (0.90 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 0.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.5 mg/mL (0.90 mM); Clear solution

This protocol yields a clear solution of ≥ 0.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (5.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

純度とドキュメンテーション

バッチを選択:

純度: 99.98%

Assay: 99.98%

ee.: 99.98%

データシート (278 KB)
SDS (788 KB)
- English - EN (788 KB)
- Français - FR (788 KB)
- Deutsch - DE (788 KB)
- Norwegian - NO (788 KB)
- Español - ES (788 KB)
- Swedish - SV (788 KB)
- Italian - IT (788 KB)
- Korean - KR (788 KB)
- Portuguese - PT (788 KB)
COA (2659 KB)
元素分析報告書 (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
取扱説明書 (2659 KB)

参考文献

[1]. Jang JC, et al. Bedaquiline susceptibility test for totally drug-resistant tuberculosis Mycobacterium tuberculosis. J Microbiol. 2017 Apr 20. [Content Brief]

[2]. Sarathy JP, et al. TBAJ-876 displays Bedaquiline-like mycobactericidal potency without retaining the parental drug's uncoupler activity. Antimicrob Agents Chemother. 2019 Nov 11. [Content Brief]

[3]. Chahine EB, et al. Bedaquiline: a novel diarylquinoline for multidrug-resistant tuberculosis. Ann Pharmacother. 2014 Jan;48(1):107-15. [Content Brief]

[4]. Pang Y, et al. In Vitro Activity of Bedaquiline against Nontuberculous Mycobacteria in China. Antimicrob Agents Chemother. 2017 Apr 24;61(5). [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.8002 mL	9.0009 mL	18.0018 mL	45.0045 mL
	5 mM	0.3600 mL	1.8002 mL	3.6004 mL	9.0009 mL
	10 mM	0.1800 mL	0.9001 mL	1.8002 mL	4.5005 mL
	15 mM	0.1200 mL	0.6001 mL	1.2001 mL	3.0003 mL
	20 mM	0.0900 mL	0.4500 mL	0.9001 mL	2.2502 mL

Keywords

Bedaquiline

56 Cited Publications

100 mg お問い合わせ

Subscribe to the

MedChemExpress

Newsletter

製品名:
製品番号:
数量:
日本の代理先をお選びください:

製品名:
CAS 番号:
生物種:
純度:
数量:

Bedaquiline

Anti-Infection Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Antibacterial Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Rare Diseases Drug Library

EMA-Approved Drug Library

Heterocyclic Compound Library

Off-patent Drug Library

Anti-tuberculosis Compound Library

Mitochondrial Toxicity Compound Library

Anti-Drug-Resistant Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 Bedaquiline

Antibiotic アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (56)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Bedaquiline

Anti-Infection Compound Library

FDA-Approved Drug Library

Drug Repurposing Compound Library

Antibacterial Compound Library

Orally Active Compound Library

FDA Approved & Pharmacopeial Drug Library

Antibiotics Library

Rare Diseases Drug Library

EMA-Approved Drug Library

Heterocyclic Compound Library

Off-patent Drug Library

Anti-tuberculosis Compound Library

Mitochondrial Toxicity Compound Library

Anti-Drug-Resistant Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

FDA-Approved Drug Library Plus

FDA-Approved Drug Library Mini

Bioactive Compound Library

High-Throughput Bioactive Compound Library

MedChemExpress（MCE）の使用を引用している文献 Bedaquiline

Antibiotic アイソフォーム固有の製品をすべて表示

生物活性

化学情報

Publications (56)

溶剤 & 溶解度

純度とドキュメンテーション

参考文献

Help & FAQs

Complete Stock Solution Preparation Table

Bedaquiline 関連分類

HY-14881 関連分類